Home>> Business>>The FDA reportedly forces J&J to scrap about 60 million doses of its Covid vaccine

The FDA reportedly forces J&J to scrap about 60 million doses of its Covid vaccine

The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. At this Baltimore Lab, 15 Million Doses Of Johnson & Johnson Vaccine were ruined, which will delay shipments of the vaccine in the United States.

Tasos Katopodis | Getty Images

Federal regulators are forcing Johnson & Johnson to scrap about 60 million doses of Covid-19 vaccine produced at a troubled Baltimore plant run by Emergent BioSolutions due to possible contamination, the New York Times reported Friday, citing people familiar with the matter.

The plant was shuttered in April after an inspection revealed several violations, including possible contamination of J&J’s vaccines with a key ingredient from AstraZeneca’s Covid vaccine. About 170 million doses of both vaccines were in question after the inspection, the Times reported.

The FDA confirmed to CNBC that several batches weren’t “suitable for use,” without confirming the exact number of doses that were discarded. It said it was clearing two batches of vaccine materials manufactured at the plant for use, according to an emailed statement. The Associated Press reported that the two batches would account for 10 million doses.

“The FDA has determined several other batches are not suitable for use, but additional batches are still under review and the agency will keep the public informed as those reviews are completed,” the agency said in an emailed statement.  

The U.S. currently has more than enough doses of two other vaccines that were approved from Pfizer and Moderna to finish vaccinating the American population.

About 10 million doses of the Johnson & Johnson vaccine will still be distributed in the U.S. and donated to other countries. The salvaged doses will come with a warning stating federal regulators could not guarantee that the manufacturing plant’s operator, Emergent BioSolutions, followed good manufacturing practices, the Times reported.

“Before making this decision, the FDA conducted a thorough review of facility records and the results of quality testing performed by the manufacturer,” the agency said. “While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management.”

The Biden administration planned to donate more doses of the shots, but those plans were stifled by the investigation into the Emergent facility.

The World Health Organization said that 11 billion doses are needed around the world to help stop the pandemic from worsening. The U.S. is buying 500 million doses of Pfizer’s two-shot vaccine to distribute to countries in need, President Joe Biden is expected to announce at this weekend’s G-7 meetings.

CNBC’s Berkeley Lovelace Jr. contributed to this article.


Please disable Adblock!

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: